Alpha-synuclein in Cerebrospinal Fluid to Differentiate Alzheimer's Disease From Lewy Body Disease.

Conditions

Alzheimer's Disease and Lewy Body Disease

Brief summary

Patients with memory disorders are experiencing different trends which are difficult to predict. Moreover, the distinction between Lewy body disease and Alzheimer's disease is not easy as both diseases can present similar symptoms. Nowadays, routine examinations exist and can improve the diagnosis but there are not specific enough of one of those two pathologies. Lewy body disease is characterized by the presence of particular structures in patient's brain, called Lewy body, composed of a protein called alpha-synuclein. The aim of this study is to measure the rate of alpha-synuclein in cerebrospinal fluid. This measurement could allow us to differentiate patient with Alzheimer's disease from those with Lewy body disease.

Blanc F, Cretin B, Muller C, Botzung A, Sanna L, Bousiges O, Ravier A, Schorr B, Anthony P, Philippi N, Demuynck C, Sauleau E.

2025-11-18

10.1007/s11357-025-01976-0

Neural correlates of neurovisual deficits in prodromal and mild dementia with Lewy bodies: A voxel-based morphometry study.

Moreau A, Tisserand A, Sanna L, Botzung A, Blanc F, Philippi N.

2025-10-27

10.1177/13872877251389634

Salience and frontoparietal network impairments across disease stages in dementia with Lewy bodies: A comparative functional MRI study with Alzheimer's disease.

Gabriel V, Chabran E, Sourty M, Cretin B, Philippi N, Muller C, Anthony P, Demuynck C, Loureiro de Sousa P, Botzung A, Sanna L, Bousiges O, Blanc F.

2025-10-17

10.1177/13872877251386844

Functional Connectivity Changes Associated With Depression in Dementia With Lewy Bodies

Manon Querry, Anne Botzung, Marion Sourty, Eléna Chabran, Léa Sanna et al. (13 authors)

International Journal of Geriatric Psychiatry2025-02-261 citations

10.1002/gps.70058

Dementia with Lewy bodies and gait neural basis: a cross-sectional study.

Sainsily-Cesarus A, Schmitt E, Landre L, Botzung A, Rauch L, Demuynck C, Philippi N, de Sousa PL, Mutter C, Cretin B, Martin-Hunyadi C, Blanc F.

2024-07-302 citations

10.1186/s13195-024-01539-z

Involvement of ApoE4 in dementia with Lewy bodies in the prodromal and demented stages: evaluation of the Strasbourg cohort.

Bousiges O, Cretin B, Muller C, Botzung A, Sanna L, Anthony P, Philippi N, Demuynck C, Blanc F.

2023-08-315 citations

10.1007/s11357-023-00883-6

Association of cerebral microbleeds with cerebrospinal fluid Alzheimer‐biomarkers and clinical symptoms in early dementia with Lewy bodies

Aline Mendes, Vincent Noblet, Mary Mondino, Paulo Loureiro de Sousa, Sumayya Manji et al. (15 authors)

International Journal of Geriatric Psychiatry2020-12-1013 citations

10.1002/gps.5485

Differential diagnostic value of total alpha-synuclein assay in the cerebrospinal fluid between Alzheimer's disease and dementia with Lewy bodies from the prodromal stage.

Bousiges O, Philippi N, Lavaux T, Perret-Liaudet A, Lachmann I, Schaeffer-Agalède C, Anthony P, Botzung A, Rauch L, Jung B, de Sousa PL, Demuynck C, Martin-Hunyadi C, Cretin B, Blanc F.

2020-09-2926 citations

10.1186/s13195-020-00684-5

P2‐327: CEREBRAL MICROBLEEDS IN EARLY STAGES OF DEMENTIA WITH LEWY BODIES ARE NOT ASSOCIATED WITH CLINICAL SYMPTOMS OR ALZHEIMER'S DISEASE CSF BIOMARKERS

Aline Mendes, Vincent Noblet, Mary Mondino, Paulo Loureiro de Sousa, Sumayya Manji et al. (13 authors)

Alzheimer s & Dementia2019-07-01

10.1016/j.jalz.2019.06.2734

Interventions

OTHERMRI

PROCEDURElumbar puncture

BEHAVIORALneuropsychological tests

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

45 Years to No maximum

Healthy volunteers

No

Inclusion criteria

* At least 45 years of age * Subject agrees to participate in the study * Subject meets the criteria Dubois et al., 2007. for diagnosis of probable AD. * Subject with a syndromic presentation of mild cognitive impairment or mild dementia * Subject has a study partner who is able to provide accurate information about the patient * Subject affiliated to a social security scheme

Exclusion criteria

* Patient who meets both AD and Lewy Body disease criteria * Contraindications to lumbar puncture * Contraindications to an MRI scan * Subject who is not affiliated to a social security scheme * Subject under guardianship or curatorship * Subject under judicial protection * Subject refuses to participate in the study * Subject has evidence of clinically relevant neurological disorder (fronto-temporal dementia, brain tumor, stroke, …) that led to persistent cognitive disorders * Subject has evidence of clinically relevant psychiatric disorders (schizophrenia, major depression, …) * Pregnant or attempting to become pregnant women * Subject's vision and audition is sufficient for neuropsychological tests's assessment, based on the investigator's judgment.

Design outcomes

Primary

Measure	Time frame
rate of alpha-synuclein in cerebrospinal fluid	Day one.

Countries

France

Outcome results

None listed